MSX-122 is primarily researched for its potential therapeutic applications in cancer treatment. It functions as a selective inhibitor of CXCR4, a chemokine receptor that plays a critical role in tumor growth, metastasis, and angiogenesis. By blocking CXCR4, MSX-122 aims to disrupt the signaling pathways that promote cancer cell migration and survival, particularly in breast cancer and other malignancies. Its application is being explored in preclinical studies to assess its efficacy in reducing tumor spread and enhancing the effectiveness of existing cancer therapies. Additionally, it may have potential in addressing inflammatory diseases due to its role in modulating immune cell trafficking. Further research is ongoing to validate its safety and therapeutic benefits in clinical settings.